Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis

2014 ◽  
Vol 341 (1-2) ◽  
pp. 22-27 ◽  
Author(s):  
Michael Kaufman ◽  
Gabriel Pardo ◽  
Howard Rossman ◽  
Marianne T. Sweetser ◽  
Fiona Forrestal ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Relapsing Remitting ◽  
Natalizumab Treatment ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis

2018 ◽  
Vol 41 (6) ◽  
pp. 199-201 ◽  
Author(s):  
Hussein Algahtani ◽  
Bader Shirah ◽  
Hind Abobaker ◽  
Nebras Alghanaim ◽  
Fatemah Kamel
Keyword(s):  
Multiple Sclerosis ◽  
Relapsing Remitting ◽  
Natalizumab Treatment ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Natalizumab restores evoked potential abnormalities in patients with relapsing–remitting multiple sclerosis

2010 ◽  
Vol 17 (2) ◽  
pp. 198-203 ◽  
Author(s):  
Sven G Meuth ◽  
Stefan Bittner ◽  
Carola Seiler ◽  
Kerstin Göbel ◽  
Heinz Wiendl
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Motor Evoked Potentials ◽  
Sum Score ◽  
Relapsing Remitting ◽  
Natalizumab Treatment ◽  
Remitting Multiple Sclerosis ◽  
Sum Scores ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis

Background and Objective: The objective of this study was to examine the effects of natalizumab on functional parameters assessed by evoked potentials (visual [VEP], somatosensory [SEP] and motor evoked potentials [MEP]) in a cohort study in relapsing–remitting multiple sclerosis patients. Methods: EP data of 44 patients examined 12 months prior to natalizumab treatment, at the timepoint of treatment initiation and 1 year later were compared. Sum scores (VEP, MEP, SEP) were evaluated and correlated with the Expanded Disability Status Scale. Results: Improvement of the VEP sum score was found in 33% of natalizumab-treated patients but only in 9% of the same patients prior to treatment ( p = 0.041). A comparable situation was found for SEP (improvement: 32% versus 5%; worsening: 11% versus 37%; p = 0.027). For MEP no significant differences were seen (improvement: 10% versus 18%; worsening: 5% versus 29%; p = 0.60). EP recordings (VEP = SEP > MEP) have the capacity to demonstrate treatment effects of natalizumab on a functional level. Conclusions: Natalizumab therapy increases the percentage of patients showing stable or even ameliorated electrophysiological parameters in the investigated functional systems.

scholarly journals Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis

2019 ◽  
Author(s):  
Marina Rodrigues Lima ◽  
Luis Arthur Brasil Gadelha Farias ◽  
Maycon Fellipe da Ponte ◽  
Luís Edmundo Teixeira de Arruda Furtado
Keyword(s):  
Multiple Sclerosis ◽  
Physical Disability ◽  
Cytomegalovirus Infection ◽  
Cytomegalovirus Disease ◽  
New Techniques ◽  
Relapsing Remitting ◽  
Natalizumab Treatment ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Natalizumab is indicated as monotherapy for the treatment of relapsing-remitting multiple sclerosis; it prevents outbreaks and delays the progression of physical disability. Here, we report the case of a 30-year-old patient with multiple sclerosis receiving natalizumab as monotherapy who subsequently developed self-limited cytomegalovirus disease. Cytomegalovirus infection has been reported during treatment with natalizumab, and in this study, we use new techniques to analyze the possible association of cytomegalovirus infection with natalizumab.

Sign in / Sign up

Export Citation Format

Share Document